The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cardiff Oncology's Revenue for the
three
months ended in Mar. 2026 was $0.04 Mil. Cardiff Oncology's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.19 Mil.
Hence, Cardiff Oncology's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.22.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cardiff Oncology Receivables Turnover Related Terms
Cardiff Oncology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRDF vs MAIA, TELO, OSTX: Receivables Turnover Comparison
For the Biotechnology subindustry, Cardiff Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Receivables Turnover of 0.22 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #734 out of 841 companies in the Biotechnology industry, placing it in the top 87.3%.
Is Cardiff Oncology's Receivables Turnover too high?
Cardiff Oncology's current Receivables Turnover is 0.22. The Biotechnology industry median Receivables Turnover is 5.29. Cardiff Oncology's value of 0.22 is 95.8% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #734 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Receivables Turnover compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #734 out of 841 companies for Receivables Turnover. This places Cardiff Oncology in the lower half of its industry. The industry median Receivables Turnover is 5.29. Cardiff Oncology's value of 0.22 is 95.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Receivables Turnover of 0.22 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Receivables Turnover is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Fairly Valued. The stock's GF Value™ is $1.41, compared to a current price of $1.33 — trading 6% below its estimated fair value. The current Receivables Turnover is 0.22 and 95.8% below the Biotechnology industry median of 5.29. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Receivables Turnover is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.33 is trading 6% below its estimated GF Value™ of $1.41.
GuruFocus considers Cardiff Oncology to be Fairly Valued.
Key valuation signals for CRDF:
Receivables Turnover: 0.22
GF Value™: $1.41 vs. price of $1.33 (6% below fair value)
Industry Position: 95.8% below the Biotechnology median (#734 of 841)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score
Get the complete analysis for CRDF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
